Trial Profile
A Multicentre Open, Non Comparative Study of the Safety of Ramipril (Tritace) 10 mg/Day in Prevention of Cardiovascular Events in High-risk Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2010
Price :
$35
*
At a glance
- Drugs Ramipril (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors Sanofi
- 29 Jan 2010 New trial record